← brief for 2026-08-21 · Regeneration & devices

Osteoactivin/GPNMB as a candidate biomarker of diabetic nephropathy in type 2 diabetes: associations with angiogenic and kidney injury biomarkers.

Article D Not peer reviewed Preclinical

Key takeaways

This study used human kidney tissue to evaluate osteoactivin as a biomarker for diabetic nephropathy. It is not a human trial.

Abu-Farha M · Marafie S · Alhemoud L · Al Shawaf E · Malek R · Almuharib J · Devarajan S · Al-Khairi I · Cherian P · Ali H · Almutairi AF · Taher I

Article · PubMed, CKD severity and reversal · 2026 Aug 6
https://pubmed.ncbi.nlm.nih.gov/42625696/